The DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Reduced cancer incidence among patients with schizophrenia
Open accessAbstract
BACKGROUND: The incidence of cancer in patients with schizophrenia has been conversely reported to be higher, lower, or similar to that in the general population. The effects of lifestyle factors such as excess smoking, exposure to neuroleptic medications, and genetic factors that may influence the incidence of cancer in this group are not clear. The current study was performed to evaluate the frequency of cancer in a large cohort of patients with schizophrenia and to determine the standardized incidence ratios (SIRs) of any malignancy in this group. METHODS: Data regarding the design, setting, and participants of the current study were analyzed from a cohort of 3226 patients with schizophrenia who were enrolled in the computerized health registry of the Abarbanel Mental Health Center between1993–2003. The mean age of the patients at the time of the diagnosis of cancer was 49 ± 14.7 years, with the majority of patients (61%) being male. All patients with schizophrenia records in the database were combined with the records of the Israeli National Cancer Registry to identify pathologically confirmed cancer comorbidity. The cancer incidence rates among patients with schizophrenia were compared with the expected incidence in an age‐matched and gender‐matched general population sample for the same time interval. RESULTS: Among 1247 female patients with schizophrenia, 22 (1.8%) developed breast cancer and 68 (5.5%) developed cancers of any type. Fifty‐two of the 1979 male schizophrenic patients (2.6%) developed cancer. The SIRs were 0.58 (95% confidence interval [95% CI], 0.48–0.69) with a P value of < 0.05 for all cancers in the cohort, and 0.60 (95% CI, 0.37–0.90) for female breast cancer. CONCLUSIONS: The results of the current study demonstrate a reduced risk of cancer in patients with schizophrenia. The mechanisms responsible for the lower risk need be investigated further. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Some studies have demonstrated a decreased cancer risk in schizophrenia (440-448).”
From Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care (2011) · cites this paper as [447]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The 1986 census of population and housing
Cornish, J. K. (1985) · Journal of the Australian Population Association · doi:10.1007/bf03041202 · Cited by 1,410
Causes of the excess mortality of schizophrenia
Brown, S., Inskip, H., & Barraclough, B. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.3.212 · Cited by 1,087
Medical Comorbidity in Schizophrenia
Jeste, D. V., Gladsjo, J. A., Lindamer, L. A., & Lacro, J. P. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.3.413 · Cited by 617
Schizophrenia and smoking: an epidemiological survey in a state hospital
de León, J., Dadvand, M., Canuso, C. M., Odom-White, A., Stanilla, J. K., & Simpson, G. M. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.3.453 · Cited by 417
Incidence of Cancer Among Persons With Schizophrenia and Their Relatives
Lichtermann, D., Ekelund, J., Pukkala, E., Tanskanen, A., & Lönnqvist, J. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.6.573 · Cited by 292 · cited 7×
“Conversely, Lichtermann et al.1 reported on a higher overall cancer risk, with nearly half of the excess cases attributable to lung cancer, yet the incidence of breast cancer was unchanged.”
BackgroundResultInfluentialElevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects
Halbreich, U. M., Kinon, B. J., Gilmore, J. A., & Kahn, L. (2002) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(02)00112-9 · Cited by 248
Premature Deaths in Schizophrenia and Affective Disorders
Tsuang, M. T. (1980) · Archives of General Psychiatry · doi:10.1001/archpsyc.1980.01780220017001 · Cited by 198
Dickerson, F., McNary, S. W., Brown, C. H., Kreyenbuhl, J. A., Goldberg, R. W., & Dixon, L. B. (2003) · Medical Care · doi:10.1097/01.mlr.0000053440.18761.f0 · Cited by 157
The occurence of cancer in first admitted schizophrenic patients
Mortensen, P. B. (1994) · Schizophrenia Research · doi:10.1016/0920-9964(94)90028-0 · Cited by 142
Mortality and causes of death in schizophrenic patients in Denmark
Mortensen, P. B., & Juel, K. (1990) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1990.tb05466.x · Cited by 138
Flagged first, then by citations
1 of the 26 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Dupont A, 1986, Psychiatric case registers in public health, 229
- Central Bureau of Statistics of Israel, 2002, Census of Population and Housing, 2
- Shalev AY, 1994, Structured clinical interview for axis I DSM‐IV patient edition
- 10.1016/S0920-9964(02)00430-9 · DOI
Cited by
Sorted by citations
Items 101–159 of 159
Mueller, F. S., Amport, R., Notter, T., Schalbetter, S. M., Lin, H.-Y., Garajovà, Z., Amini, P., Weber‐Stadlbauer, U., & Markkanen, E. (2022) · BMC Biology · doi:10.1186/s12915-022-01377-1 · Cited by 13
Stress Hormones: Emerging Targets in Gynecological Cancers
Chen, G.-Q., Qiu, L., Gao, J., Wang, J., Dang, J., Li, L., Jin, Z., & Liu, X. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.699487 · Cited by 13
miR-183 as a molecular and protective biomarker for cancer in schizophrenic subjects
Rizos, E. N., Siafakas, N., Koumarianou, A. A., Katsantoni, E. Z., Filippopoulou, A., Ntounas, P., TOULOUMIS, C., Kastania, A., & Zoumpourlis, V. C. (2012) · Oncology Reports · doi:10.3892/or.2012.2052 · Cited by 14
Wang, Y., Cao, Y., Huang, X., Yu, T., Wei, Z., McGrath, J. J., Xu, F., Bi, Y., Li, X., Yang, F., et al. (2016) · Scientific Reports · doi:10.1038/srep26688 · Cited by 13
Zhang, H., Li, D., Su, Y., Jiang, S., Xu, Y., Jiang, K., & Cui, D. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.559273 · Cited by 11
Chen, L., Hung, Y., Chen, Y., Yang, S., Pan, C. H., Chen, C., & Kuo, C. J. (2016) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796016000883 · Cited by 11
Cholinergic mechanisms in schizophrenia: Current concepts
Raedler, T. J., & Tandon, R. (2006) · Current Psychosis & Therapeutics Reports · doi:10.1007/bf02629410 · Cited by 11
Ishihara, K., Takata, K., & Mizutani, K. (2023) · Life · doi:10.3390/life13010221 · Cited by 10
Schizophrenia and cancer: Is angiogenesis a missed link?
Lopes, R., Soares, R. A., Figueiredo‐Braga, M., & Coelho, R. C. (2014) · Life Sciences · doi:10.1016/j.lfs.2013.12.023 · Cited by 10
McCarter, R. V., Rosato, M., Thampi, A., Barr, R. S., & Leavey, G. (2023) · European Psychiatry · doi:10.1192/j.eurpsy.2023.2441 · Cited by 8
Cancer prevalence in Israeli men and women with schizophrenia
Agay, N., Flaks‐Manov, N., Nitzan, U., Hoshen, M., Levkovitz, Y., & Munitz, H. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.07.082 · Cited by 8
CTLA4 mRNA expression in blood is lower in schizophrenia, but not in affective disorders
Miyamoto, K., Funahashi, Y., Yoshino, Y., Kawabe, K., Yamazaki, K., Ozaki, Y., Mori, Y., Ochi, S., Iga, J., & Ueno, S. (2020) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2020.102112 · Cited by 8
Multilevel Pharmacological Effects of Antipsychotics in Potential Glioblastoma Treatment
Awuah, W. A., Alexiou, A. T., Kalmanovich, J. B., Mehta, A., Huang, H. Y. R., Abdul‐Rahman, T., Ng, J. C., Yarlagadda, R., Kamanousa, K., Kundu, M., et al. (2023) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026623666230102095836 · Cited by 7
Prostate Cancer Related JAZF1 Gene is Associated with Schizophrenia.
Wang, K., Zuo, L., Owusu, D., Pan, Y., & Luο, X. (2014) · PubMed · Cited by 7
Non-synonymous variants in the AMACR gene are associated with schizophrenia
Bespalova, I. N., Durner, M., Ritter, B. P., Angelo, G. W., Rossy-Fullana, E., Carrión‐Baralt, J. R., Schmeidler, J., & Silverman, J. M. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.08.040 · Cited by 7
Yeo, I. J., Yu, J. E., Kim, S., Kim, D. H., Jo, M., Son, D. J., Yun, J., Han, S., & Hong, J. T. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-024-01487-0 · Cited by 6
Fang, X., Yu, H., Wu, C., Tan, J., Sun, F., Qian, N., Zhou, H., Zhou, J., & Zhang, X. (2025) · BMC Medicine · doi:10.1186/s12916-025-04380-9 · Cited by 5
“…studies have suggested a lower incidence rate of neoplasms in individuals with, potentially attributed to protective biological and other mechanisms in these patients [41–43], there is growing evidence indicating a gradual increase in the incidence of neoplasms among individuals with SMI [44–46].”
Drug repositioning: examining antipsychotic drugs and their anticancer effects
Sagnak, A., & Arı, F. (2025) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-025-00562-1 · Cited by 4
Tylec, A., Dubas-Ślemp, H., Wójcicka, A., Drop, B., & Kucharska, K. (2018) · Psychiatria Polska · doi:10.12740/pp/69142 · Cited by 4
Reduced Risk of Cancer in Patients with Bipolar Affective Disorder
Rosenshfir, E., Shemesh, P., Aizenberg, D., & Barak, Y. (2011) · Neuroscience & Medicine · doi:10.4236/nm.2011.21008 · Cited by 4
Self-citationBao, R., Ng, A. K. Y., Sasaki, M. M., Selvan, M. E., Katti, A., Lee, H., Huang, L., Skol, A. D., Lavarino, C. E., Salvador, H., et al. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-20-0094 · Cited by 4
Kanmodi, R., Bankole, H. A., Oddiri, R. T., Arowosegbe, M., Alabi, R., Rahmon, S., Ahmodu, O., AbdulRasheed, B., & Muritala, R. (2023) · Current Drug Discovery Technologies · doi:10.2174/1570163820666230606113158 · Cited by 3
Melkersson, K. I. (2008) · Acta Neuropsychiatrica · doi:10.1111/j.1601-5215.2008.00313.x · Cited by 3
The effect of human GRIN1 gene 5′ functional region on gene expression regulation in vitro
Liu, Y., Wu, X., Meng, J.-H., Xing, J., Xuan, J., Xia, X., Yao, J., & Wang, B. (2021) · Gene · doi:10.1016/j.gene.2021.145973 · Cited by 3
Cancer Risk Before Schizophrenia Diagnosis in Taiwan, 1995-2009
Chen, Y.-J., Lin, G., & Li, Y.-H. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbt053 · Cited by 3
Ploeger, A. (2008) · Data Archiving and Networked Services (DANS) · Cited by 3
Association between Schizophrenia and Urinary Calculi: A Population-Based Case-Control Study
Liu, S., Lin, C.-C., Lin, H., Chen, Y., & Yu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056942 · Cited by 2
Soins palliatifs et situations psychiatriques chroniques : questionnement à partir d’un cas clinique
Rhondali, W., Perceau-Chambard, É., & Filbet, M. (2010) · Médecine Palliative · doi:10.1016/j.medpal.2010.03.006 · Cited by 2
Deciphering the paradoxical incidence of cancer in schizophrenia
Kuppili, P. P., & Nebhinani, N. (2018) · Australasian Psychiatry · doi:10.1177/1039856218797439 · Cited by 2
Unexpected benefits of allergies and cigarette smoking: two examples of paradox in neuroepidemiology
Schwartzbaum, J., Karavodin, L. M., Kapur, N., & Fisher, J. L. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511978098.016 · Cited by 2
The Interaction Between Melanoma and Psychiatric Disorder
Kisely, S. R., Lawrence, D. M., Kelly, G., Pais, J., & Crowe, E. (2011) · InTech eBooks · doi:10.5772/19020 · Cited by 2
The methodological and conceptual aspects of mortality studies in psychiatry
Biggeri, A., & Catelan, D. (2010) · Epidemiologia e Psichiatria Sociale · doi:10.1017/s1121189x00001548 · Cited by 2
Malignant Diseases and Mental Disorders - Prevalence, Mortality, Therapeutic Challenge
Pisk, S. V., Filipčić, I., Bogović, A., Milovac, Z., Laidlaw, I. T., & Caratan, S. (2017) · Socijalna psihijatrija · doi:10.24869/spsih.2017.187 · Cited by 2
Wu, C., Chiu, L., & Raturi, V. P. (2023) · Indian Journal of Gynecologic Oncology · doi:10.1007/s40944-022-00670-9 · Cited by 2
Cordella, M., & Poiani, A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9605-2_3 · Cited by 1
Lower risk of prostate cancer in schizophrenia: fact or artifact?
Gal, G., Munitz, H., & Levav, I. (2014) · The European Journal of Psychiatry · doi:10.4321/s0213-61632014000400002 · Cited by 1
Treatments for Otorhinolaryngological Patients with Psychiatric Disorders
Nishio, A., Sumi, T., Yamada, M., & Kuwahata, Y. (2013) · Nippon Jibiinkoka Gakkai Kaiho · doi:10.3950/jibiinkoka.116.97 · Cited by 1
Schizophrenia: Differential diagnosis and comorbidities
Altamura, C. A., Dragogna, F., Pozzoli, S. M., & Mauri, M. C. (2009) · Medical psychiatry · doi:10.3109/9781420080063.006 · Cited by 1
Relationship between Mental Disorders, Smoking or Alcoholism and Benign Prostate Disease
Chantada-Tirado, P., Chantada-Abal, V., Cózar-Ortiz, J. D., Tirado, C. C., Cozar-Olmo, J. M., Esteban‐Fuertes, M., Alvarez-Ossorio-Rodal, A., Fraile, J. F., Márquez-Sánchez, M.-T., Padilla-Fernández, B. Y., et al. (2024) · Clinics and Practice · doi:10.3390/clinpract14010020 · Cited by 1
Schizophrenia Spectrum Disorders and Risk for Cancer Morbidity and Mortality
Ponizovsky, A. M., Weizman, A., & Grinshpoon, A. (2011) · Springer eBooks · doi:10.1007/978-94-007-0831-0_19 · Cited by 1
Reduced Risk of Cancer in Schizophrenia, a Bridge Toward Etio-Pathology and Therapy of Both Diseases
Eskandari, M. R., Abdolmaleky, H. M., Zhou, J., & Thiagalingam, S. (2015) · Springer eBooks · doi:10.1007/978-94-017-9639-2_5 · Cited by 1
People with schizophrenia can become resilient while recovering
Liersch, S., Curtis, J., & Caputi, P. (2011) · Développement Humain Handicap et Changement Social · doi:10.7202/1087268ar · Cited by 1
Does Parkinsons Disease Dementia Reduce Cancer Risk more than Alzheimers Disease Alone?
Chen, Y.-J., Lin, G. M., Wu, Y., Tseng, W. S., Kuo, D.-J., Chu, C., & Li, Y. H. (2017) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000222 · Cited by 1
(2022) · Medical & Clinical Research · doi:10.33140/mcr.07.12.02 · Cited by 1
Nielsen, J. (2011) · Springer eBooks · doi:10.1007/978-94-007-0834-1_13 · Cited by 1
The DISC1 genetic pathway and its role in Schizophrenia development
Yengej, D. Y. (2012) · Utrecht University Repository (Utrecht University)
González-Rodríguez, A., Molina-Andreu, O., Penadés, R., Imaz, M. L., & Catalán, R. (2014) · Journal of Nursing Education and Practice · doi:10.5430/jnep.v4n4p81
Prostate Cancer Related JAZF1 Gene is Associated with
Pan, Y., Luο, X., & Wang, K. (2014)
McEachin, R. C. (2011) · World Journal of Medical Genetics · doi:10.5496/wjmg.v1.i1.4
Maj, M., Ïðåçèäåíò, È., Tasman, A., & Herrman, H. (2011)
Incidence of Gastric Cancer in the Patients with Schizophrenia: A Meta-analysis
Gao, J., Wang, Y., Jia, Z., Zhou, T., Xiangwen, Z., & Zu, G. (2021) · International Journal of Gastroenterology · doi:10.11648/j.ijg.20210502.12
(2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811351-6.00026-7
Bao, R., Ng, A. K. Y., Sasaki, M. M., Selvan, M. E., Katti, A., Lee, H., Huang, L., Skol, A. D., Lavarino, C. E., Salvador, H., et al. (2023) · doi:10.1158/1940-6207.c.6547366.v1
Bryzgalov, A. O. (2023) · Current Cancer Therapy Reviews · doi:10.2174/1573394719666230531122610
Akshija, I. (2023) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2023.1.7
Mueller, F. S., Amport, R., Notter, T., Schalbetter, S. M., Lin, H.-Y., Garajovà, Z., Amini, P., Weber‐Stadlbauer, U., & Markkanen, E. (2022) · Figshare · doi:10.6084/m9.figshare.20408703
Gouveia, M. J., & Vale, N. (2026) · Journal of Xenobiotics · doi:10.3390/jox16040125
Brown, E. M. (2014) · Scholar Commons (University of South Carolina)
Metadata
- Authors
- Barak, Y., Achiron, A., Mandel, M., Mirecki, I., & Aizenberg, D.
- Affiliations
- Tel Aviv University (IL)
- Corresponding author
- Barak, Yoram
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-11-15
- Volume
- 104
- Issue
- 12
- Pages
- 2817-2821
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1535192849
- Cited by
- 159
- References
- 26
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 3 · 2023: 11 · 2022: 8 · 2021: 9 · 2020: 8 · 2019: 7 · 2018: 10 · 2017: 4 · 2016: 9 · 2015: 8 · 2014: 12 · 2013: 11 · 2012: 7
- FWCI
- 3.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Stress, Anesthesia, and Immune Response
- Keywords
- schizophrenia, cancer incidence, breast cancer, standardized incidence ratio, cancer comorbidity, antipsychotic drugs, smoking, genetic factors, psychiatric patients
- MeSH terms
- Adult, Aged, Female, Humans, Israel, Male, Middle Aged, Neoplasms, Prognosis, Registries, Schizophrenia, Severity of Illness Index, Cohort Studies, Comorbidity, Incidence, Survival Rate, Confidence Intervals, Odds Ratio, Age Distribution, Sex Distribution, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
